Danaher Corporation $DHR Stock: Covenant Asset Management LLC Grows Position

Covenant Asset Management LLC boosted its stake in Danaher Corporation (NYSE:DHR) by 94.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,176 shares of the conglomerate’s stock after purchasing an additional 2,514 shares during the quarter. Covenant Asset Management LLC’s holdings in Danaher were worth $1,147,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of DHR. BlackRock Inc. purchased a new position in Danaher during the second quarter worth approximately $10,492,520,000. Jupiter Topco LLC acquired a new position in shares of Danaher in the 2nd quarter valued at $1,456,317,000. Generation Investment Management LLP purchased a new stake in shares of Danaher during the 2nd quarter valued at $1,287,949,000. Bank of America Corp DE purchased a new stake in shares of Danaher during the 2nd quarter valued at $993,846,000. Finally, Legal & General Group Plc purchased a new stake in shares of Danaher during the 2nd quarter valued at $801,056,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments

Danaher Trading Up 0.8%

Shares of DHR stock opened at $224.65 on Thursday. The firm’s 50 day moving average price is $212.92 and its two-hundred day moving average price is $195.39. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The stock has a market cap of $157.93 billion, a price-to-earnings ratio of 39.90, a price-to-earnings-growth ratio of 2.80 and a beta of 0.76.

Danaher (NYSE:DHR) last posted its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same quarter in the previous year, the business posted $0.77 EPS. The business’s quarterly revenue was up 5.5% on a year-over-year basis. On average, analysts anticipate that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s dividend payout ratio (DPR) is 28.42%.

Analyst Ratings Changes

DHR has been the subject of a number of research analyst reports. UBS Group assumed coverage on Danaher in a report on Wednesday, September 9th. They set a “buy” rating and a $250.00 price objective for the company. TD Cowen lifted their target price on Danaher from $236.00 to $255.00 and gave the company a “buy” rating in a report on Tuesday. Barclays boosted their price target on Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Stifel Nicolaus dropped their price target on Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. Finally, The Goldman Sachs Group raised their price objective on Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $235.41.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.